Pharma BD Deal Intelligence
The deal that built modern UCB neurology — Vimpat became a genuine blockbuster, but a 2008 product recall and two years of profit collapse show it was far from a clean win
Full analysis, sources & comparables →Deal positions UCB as a focused mid-cap CNS specialist; family-controlled Schwarz (~60% holding) backed the friendly takeover, bringing late-stage Neupro and…
UCB to acquire Schwarz Pharma at €91.1/share (€50 cash + 0.8735 UCB share), valuing Schwarz at €4.4B; expected synergies >€300M annually after 3 years;…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
CNS (Parkinson's, epilepsy, RLS); EUR 4.4B; lacosamide pipeline
The deal that built modern UCB neurology — Vimpat became a genuine blockbuster, but a 2008 product recall and two years of profit collapse show it was far from a clean win
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB SA / Schwarz Pharma AG (this deal) | 2006 | $5.6B | 80 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals